Treatment Profile #3
Clinical Profile & Review
An evidence-based profile of the PDE5 inhibitor vardenafil, including its pharmacology, timing, formulations, clinical evidence, safety considerations, and distinctive QT-interval warning.
European Levitra product information describes dosing approximately 25–60 minutes before sexual activity.
Film-coated vardenafil is available in 5 mg, 10 mg, and 20 mg strengths.
The former U.S. Staxyn formulation was a 10 mg orally disintegrating tablet (ODT), placed on the tongue and taken without liquid.
FDA labeling states that the 10 mg orally disintegrating form produces higher systemic exposure than the 10 mg film-coated tablet. The two forms should therefore not be treated as interchangeable dose-for-dose.
Sexual stimulation causes the release of nitric oxide in penile tissue.
Nitric oxide increases a signalling molecule called cyclic GMP (cGMP).
cGMP relaxes smooth muscle in penile tissue and increases blood flow.
The enzyme PDE5 normally breaks down cGMP. Vardenafil inhibits PDE5, allowing the cGMP signal to persist longer.
Vardenafil does not independently create sexual arousal. Sexual stimulation is still required.
Laboratory (in vitro) studies show vardenafil is selective for PDE5 relative to other phosphodiesterase enzymes:
These are in vitro biochemical findings — a pharmacology fact, not a clinical score. They do not by themselves show that vardenafil causes fewer visual, muscular, or cardiovascular side effects than other PDE5 inhibitors.
Vardenafil is an on-demand ED medication with a relatively short half-life compared with tadalafil. Clinical trials demonstrated effectiveness in general ED populations and also studied men with diabetes and men with ED following radical prostatectomy. This does not make it universally superior for these groups.
Vardenafil has randomized, placebo-controlled clinical evidence supporting its efficacy in erectile dysfunction.
Evidence in Men With Diabetes
Controlled clinical trials demonstrated statistically significant improvements in erectile-function measures in men with diabetes. Trial results describe group averages and do not guarantee effectiveness for any individual.
Commonly reported possible adverse effects — not expected effects — can include:
Contraindicated
QT Warning
Vardenafil carries a specific QT-interval warning. Under current U.S. labeling, patients with congenital QT prolongation and patients taking Class IA antiarrhythmics (such as quinidine or procainamide) or Class III antiarrhythmics (such as amiodarone or sotalol) are advised to avoid vardenafil.
Use Caution
Seek Urgent Medical Attention For
Half-life describes how quickly drug levels fall in the blood. It is not identical to the precise duration of erectile response and should not be read as "how long the drug works."
SynMale ratings are editorial comparison tools. They are not clinical success rates, safety guarantees, or predictions of individual response.
SynMale numerical ratings are editorial comparison tools informed by:
These numbers are not efficacy percentages, clinical success rates, or predictions of individual response.
Full methodology →Biochemical selectivity is reported separately above as a pharmacology fact and is not part of the scorecard.
Vardenafil is a well-established PDE5 inhibitor with strong clinical evidence for erectile dysfunction and an on-demand profile broadly similar in duration to sildenafil. Its most distinctive safety consideration among commonly used PDE5 inhibitors is its QT-interval warning. Formulation matters: orally disintegrating vardenafil should not automatically be treated as dose-equivalent to film-coated tablets.
Specific peer-reviewed trial citations will be added after editorial and medical review.